Lincoln Pharma.

Why is Lincoln Pharmaceuticals Ltd falling/rising?

As of 24-Aug, Lincoln Pharmaceuticals Ltd's stock price is falling to 611.90, down 0.87%. This decline is part of a broader trend of underperformance, with recent negative returns and decreased investor participation contributing to weakening momentum.

As of 24-Aug, Lincoln Pharmaceuticals Ltd's stock price is falling, currently at 611.90, reflecting a decrease of 5.4 points or 0.87%. This decline is part of a broader trend, as the stock has underperformed its sector by 0.91% today and has experienced consecutive falls over the last two days, totaling a drop of 1.81%. <BR><BR>In terms of recent performance, the stock has shown a negative return of 1.64% over the past week, while the benchmark Sensex has only declined by 0.46%. Although the stock has performed well over longer periods, with a year-to-date increase of 26.63% compared to a 9.21% drop in the Sensex, the recent short-term trends indicate a weakening momentum. <BR><BR>Additionally, there has been a notable decrease in investor participation, with delivery volume on August 21 falling by 44.39% compared to the 5-day average. This decline in trading activity may contribute to the stock's downward pressure. Despite being above the 20-day, 50-day, and 200-day moving averages, the stock is currently below the 5-day and 100-day moving averages, suggesting a potential shift in market sentiment. Overall, these factors collectively explain the current decline in Lincoln Pharmaceuticals Ltd's stock price.

Which are the latest news on Lincoln Pharma.?

Should I buy, sell or hold Lincoln Pharmaceuticals Ltd?

Who are in the management team of Lincoln Pharma.?

The management team of Lincoln Pharma includes Chairman Kishorbhai M Shah, Managing Director Mahendra G Patel, and several Whole-time Directors, along with independent directors and Company Secretary Trusha Shah, bringing diverse expertise to the company.

The management team of Lincoln Pharma includes the following individuals:<BR><BR>1. **Kishorbhai M Shah** - Chairman (Non-Executive)<BR>2. **Mahendra G Patel** - Managing Director<BR>3. **Hasmukhbhai I Patel** - Whole-time Director<BR>4. **Munjal Mahendrabhai Patel** - Whole-time Director<BR>5. **Aashish R Patel** - Whole-time Director<BR>6. **Anand Arvindbhai Patel** - Whole-time Director<BR>7. **Trusha Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board includes independent directors:<BR><BR>1. **Pirabhai R Suthar** - Independent Director<BR>2. **Meha Patel** - Independent Director<BR>3. **Saurin J Parikh** - Independent Director<BR><BR>Lastly, **Rajnikant G Patel** serves as a Director. This diverse team brings a range of expertise to the company.

What does Lincoln Pharma. do?

Lincoln Pharmaceuticals Ltd manufactures and trades pharmaceutical products, operating as a micro-cap company with a market cap of INR 1,203 Cr. As of June 2026, it reported net sales of 177 Cr and a net profit of 36 Cr.

Overview: <BR>Lincoln Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and operates as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in January 1979 as a Partnership Firm and was converted into a Public Limited Company in January 1995. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 177 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 36 Cr (Quarterly Results - Jun 2026) <BR>- Market Cap: INR 1,203 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 13.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.30% <BR>- Debt-Equity: -0.31 <BR>- Return on Equity: 11.60% <BR>- Price to Book: 1.56 <BR><BR>Contact Details: <BR>Address: Lincoln House B/H Satyam Compe, Science City Road Sola Ahmedabad Gujarat : 380060 <BR>Tel: 91-079-67778000 <BR>Email: info@lincolnpharma.com <BR>Website: http://www.lincolnpharma.com

Who are the peers of the Lincoln Pharma.?

Lincoln Pharma's peers include Jagsonpal Pharma, Syncom Formulations, Amrutanjan Health, Fermenta Biotec, Bajaj Healthcare, Sigachi Industries, Themis Medicare, Bharat Parenter, Accent Microcell, and Remus Pharma. In terms of management risk, growth, and capital structure, Lincoln Pharma shows average performance compared to its peers, with a 1-year return of 13.55%.

Peers: The peers of Lincoln Pharma are Jagsonpal Pharma, Syncom Formul., Amrutanjan Healt, Fermenta Biotec., Bajaj Healthcare, Sigachi Indust., Themis Medicare, Bharat Parenter., Accent Microcell, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, Sigachi Indust., and Accent Microcell, while Average management risk is found at Jagsonpal Pharma, Syncom Formul., Fermenta Biotec., Lincoln Pharma, Bajaj Healthcare, Themis Medicare, and Remus Pharma. Below Average management risk is noted at Bharat Parenter. In terms of Growth, Good growth is seen at Accent Microcell, while Average growth is observed at Jagsonpal Pharma, Syncom Formul., Fermenta Biotec., Lincoln Pharma, Bajaj Healthcare, Themis Medicare, and Remus Pharma, and Below Average growth is noted at Amrutanjan Healt and Bharat Parenter. Excellent capital structure is present at Jagsonpal Pharma, Syncom Formul., Amrutanjan Healt, Lincoln Pharma, Sigachi Indust., and Accent Microcell, while Below Average capital structure is found at Fermenta Biotec., Bajaj Healthcare, Themis Medicare, and Bharat Parenter.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fermenta Biotec. at 27.76%, while the peer with the lowest is Amrutanjan Healt at -27.87%. Lincoln Pharma's 1-year return is 13.55%, which is higher than that of Amrutanjan Healt but lower than Fermenta Biotec. Additionally, Bajaj Healthcare, Amrutanjan Healt, and Themis Medicare have negative six-month returns.

How big is Lincoln Pharma.?

As of 14th August, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,227.12 Cr, with recent net sales of 694.24 Cr and a net profit of 96.44 Cr.

As of 14th August, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,227.12 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lincoln Pharmaceuticals reported Net Sales of 694.24 Cr and a Net Profit of 96.44 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 671.67 Cr and Total Assets of 797.01 Cr.

Are Lincoln Pharmaceuticals Ltd latest results good or bad?

Lincoln Pharmaceuticals Ltd's latest results are mixed; while net sales increased by 11.36% year-on-year to ₹187.28 crores, net profit fell by 59.34% from the previous quarter, raising concerns about profitability and operational efficiency. Investors should remain cautious as the company faces challenges despite revenue growth.

Lincoln Pharmaceuticals Ltd's latest results present a mixed picture. In Q4 FY26, the company achieved a net profit of ₹11.63 crores, which is a slight increase of 0.43% year-on-year. However, this figure represents a significant decline of 59.34% compared to the previous quarter, which raises concerns about profitability.<BR><BR>On the positive side, net sales grew by 11.36% year-on-year, reaching ₹187.28 crores, indicating strong revenue momentum driven by domestic demand and exports. However, the operating margin decreased to 13.27%, down 262 basis points from the previous year, reflecting rising input costs and operational challenges.<BR><BR>Overall, while Lincoln Pharmaceuticals showed resilience in revenue growth, the substantial drop in net profit and margin compression suggest underlying issues that need to be addressed. Investors should be cautious and monitor the company's ability to improve profitability and operational efficiency in the coming quarters.

When is the next results date for Lincoln Pharmaceuticals Ltd?

The next results date for Lincoln Pharmaceuticals Ltd is 13 August 2026.

The next results date for Lincoln Pharmaceuticals Ltd is scheduled for 13 August 2026.

Is Lincoln Pharma. technically bullish or bearish?

As of November 20, 2025, Lincoln Pharma's technical outlook is bearish, driven by bearish daily moving averages and KST indicators, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 20 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages, which are bearish, and the KST on both weekly and monthly time frames, which are also bearish. The monthly Bollinger Bands indicate a mildly bearish trend, while the Dow Theory shows a mildly bullish signal on the weekly but remains bearish on the monthly. Overall, the combination of these indicators suggests a bearish outlook for Lincoln Pharma.

How has been the historical performance of Lincoln Pharma.?

Lincoln Pharma has shown consistent growth in net sales and profits, with net sales increasing from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, and operating profit rising from 72.87 Cr to 123.97 Cr during the same period, despite some fluctuations in profit margins. Total assets and liabilities have also significantly increased, reflecting robust overall growth.

Answer:<BR>The historical performance of Lincoln Pharma shows a consistent growth trajectory in net sales and profit over the years.<BR><BR>Breakdown:<BR>Lincoln Pharma's net sales have increased from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, reflecting a steady upward trend. Total operating income has followed a similar pattern, rising from 366.15 Cr to 623.23 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 298.91 Cr in March 2019 to 521.74 Cr in March 2025. Despite this increase in expenses, operating profit (PBDIT) has shown resilience, climbing from 72.87 Cr to 123.97 Cr, although it peaked at 134.33 Cr in March 2024. Profit before tax reached 109.19 Cr in March 2025, down from 122.24 Cr in March 2024, while profit after tax was 82.35 Cr in March 2025, a decrease from 93.30 Cr in the previous year. The company's total assets have significantly increased from 389.39 Cr in March 2020 to 797.01 Cr in March 2025, indicating robust growth in its asset base. Total liabilities also rose from 389.39 Cr to 797.01 Cr over the same period. Cash flow from operating activities improved to 93.00 Cr in March 2025, up from 63.00 Cr in March 2024, contributing to a net cash inflow of 7.00 Cr in March 2025. Overall, Lincoln Pharma has demonstrated a solid performance with increasing revenues and profits, despite some fluctuations in profit margins and expenses.

Who are the top shareholders of the Lincoln Pharma.?

The top shareholders of Lincoln Pharma include promoter Munjal Mahendrabhai Patel with 13.37%, individual investors at 36.27%, and 53 foreign institutional investors holding 5.14%. The highest public shareholder is Kishor M. Shah with 2.39%.

The top shareholders of Lincoln Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Munjal Mahendrabhai Patel, owning 13.37% of the company. Additionally, individual investors hold a significant portion at 36.27%. In terms of institutional investment, 53 foreign institutional investors (FIIs) collectively hold 5.14%, while mutual funds have a minimal presence with holdings from 2 schemes at 0.0%. The highest public shareholder is Kishor M. Shah, who holds 2.39%.

Is Lincoln Pharma. overvalued or undervalued?

As of May 26, 2025, Lincoln Pharma is considered an attractive investment, assessed as undervalued with a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%, significantly lower than peers like Sun Pharma and Divi's Lab, indicating strong growth potential despite recent stock performance declines.

As of 26 May 2025, the valuation grade for Lincoln Pharma has moved from very attractive to attractive. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%. <BR><BR>In comparison to its peers, Lincoln Pharma's PE Ratio is significantly lower than Sun Pharma's 35.25 and Divi's Lab's 79.33, indicating a more favorable valuation. Additionally, while Lincoln Pharma has a PEG Ratio of 0.00, suggesting strong growth potential relative to its price, competitors like Cipla and Dr. Reddy's Labs have PEG Ratios of 0.97 and 14.54, respectively. Despite a recent decline in stock performance year-to-date, Lincoln Pharma has outperformed the Sensex over a three-year period, reinforcing its potential as an undervalued investment in the pharmaceuticals sector.

Has Lincoln Pharma. declared dividend?

Yes, Lincoln Pharmaceuticals Ltd has declared a 15% dividend, amounting to 1.5 per share, with an ex-date of September 15, 2023. While recent total returns show volatility, longer-term performance over five years has been positive, with a total return of 247.97%.

Lincoln Pharmaceuticals Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 15 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -37.95%, the dividend return was 0%, resulting in a total return of -37.95%.<BR><BR>Over the past year, the price return was -2.18%, the dividend return was 0%, leading to a total return of -2.18%.<BR><BR>In the 2-year period, the price return was 51.57%, the dividend return was 0.37%, culminating in a total return of 51.94%.<BR><BR>For the 3-year period, the price return was 98.05%, the dividend return was 1.06%, resulting in a total return of 99.11%.<BR><BR>In the last 4 years, the price return was 96.75%, the dividend return was 1.42%, leading to a total return of 98.17%.<BR><BR>Finally, over the past 5 years, the price return was 245.19%, the dividend return was 2.78%, resulting in a total return of 247.97%.<BR><BR>Overall, while Lincoln Pharmaceuticals has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year. However, the longer-term returns show a more positive trend, especially over the 5-year period.